Heron Therapeutics
HRTX
193 hedge funds and large institutions have $1.48B invested in Heron Therapeutics in 2021 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 67 increasing their positions, 63 reducing their positions, and 24 closing their positions.
397% more call options, than puts
Call options by funds: $19.8M | Put options by funds: $3.99M
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
2% more funds holding
Funds holding: 189 → 193 (+4)
6% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 63
0.36% more ownership
Funds ownership: 99.36% → 99.71% (+0.36%)
22% less capital invested
Capital invested by funds: $1.91B → $1.48B (-$428M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$30.8M |
| 2 |
Millennium Management
New York
|
+$15M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$11M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.7M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$9.02M |
Top Sellers
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$28.4M |
| 2 |
O
OrbiMed
New York
|
-$25.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$19.4M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$18.3M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$10.1M |
HRTX Hedge Fund Activity: Q1 2021 in Review
193 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2021, worth a combined $1.48B — down 22% from $1.91B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new HRTX positions and 24 closed out — a net gain of 6 holders — while 67 added to existing stakes and 63 trimmed.
The largest buyer was UBS O'Connor, adding an estimated $30.8M. The largest seller was Artisan Partners, exiting entirely with an estimated $28.4M sold.
- 193 institutional investors held Heron Therapeutics (HRTX) as of Q1 2021, up from 189 in Q4 2020.
- Funds reported $1.48B of Heron Therapeutics stock for Q1 2021, down 22% quarter-over-quarter.
- 30 funds opened new Heron Therapeutics positions in Q1 2021 and 24 closed out, a net change of +6 holders.
- The largest Heron Therapeutics buyer in Q1 2021 was UBS O'Connor, an estimated $30.8M added.
- The largest Heron Therapeutics seller in Q1 2021 was Artisan Partners, an estimated $28.4M sold.
Based on aggregated 13F filings for Q1 2021.